We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Case Series

Stereotactic body radiation therapy for adrenal metastases: a retrospective review of a noninvasive therapeutic strategy

    Jordan Torok

    Department of Radiation Oncology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA

    Search for more papers by this author

    ,
    Rodney E Wegner

    Department of Radiation Oncology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA

    Search for more papers by this author

    ,
    Steven A Burton

    Department of Radiation Oncology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA

    Search for more papers by this author

    &
    Dwight E Heron

    † Author for correspondence

    Search for more papers by this author

    Email the corresponding author at herond2@upmc.edu

    Published Online:21 Dec 2010https://doi.org/10.2217/fon.10.165

    Abstract

    Aims: The role of radiation therapy in the treatment of adrenal metastases has traditionally been a palliative one, achieving excellent pain control with very limited toxicity. Recent studies have focused on the potential role of stereotactic body radiation therapy (SBRT) with curative intent in limited metastatic disease, its potential to reduce tumor burden and to prevent symptomatic progression. This study reports the single-institution outcomes of SBRT utilizing both single fraction and hypofractionated regimens in the treatment of adrenal metastases. Methods: A total of seven patients with nine adrenal metastases treated with SBRT at the University of Pittsburgh Cancer Institute were retrospectively studied. The primary malignancies consisted of non-small-cell lung cancer (n = 4), small-cell lung cancer (n = 1) and hepatocellular carcinoma (n = 2). Results: Five lesions were treated in a single fraction to a median prescription dose of 16 Gy (range: 10–22 Gy) to the 80% isodose line. The remaining four lesions were treated over three fractions to a median prescription dose of 27 Gy (range: 24–36 Gy), with a median prescription isodose line of 94% (range: 80–94%). Median follow-up from the primary diagnosis was 38 months (range: 7–88 months) and from SBRT was 14 months (range: 1–60 months). Follow-up imaging for six patients, and eight metastatic lesions, revealed one complete response, two partial responses and five stable lesions. Five of the lesions eventually failed locally, with a median time to failure of 12 months and actuarial local control of 63% at 1 year. The median overall survival was 8 months from SBRT. Conclusion: SBRT can be safely delivered in single fraction, or hypofractionated, regimens for the treatment of adrenal metastases.

    Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

    Bibliography

    • 1  Lenert JT, Barnet CC Jr, Kudelka AP et al.: Evaluation and surgical resection of adrenal masses in patients with a history of extra-adrenal malignancy. Surgery130(6),1060–1067 (2001).
      Medline CASGoogle Scholar
    • 2  Kung AW, Pun KK, Lam KY, Wang C, Leung CY: Addisonian crisis as presenting feature in malignancies. Cancer65(1),177–179 (1990).
      Medline CASGoogle Scholar
    • 3  Lam KY, Lo CY: Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital. Clin. Endocrinol. (Oxf.)56(1),95–101 (2002).
      MedlineGoogle Scholar
    • 4  Belleggia C, Piga A, Torresi U, Montironi R, Cellerino R: Adrenal metastasis: clinical and pathological aspects. Minerva Med.79(1),1–4 (1988).
      Medline CASGoogle Scholar
    • 5  Kim SH, Brennan MF, Russo P, Burt ME, Coit DG: The role of surgery in the treatment of clinically isolated adrenal metastasis. Cancer85(2),389–394 (1998).
      Google Scholar
    • 6  Tanvetyanon T, Robinson LA, Schell MJ et al.: Outcomes of adrenalectomy for isolated synchronous versus metachronus adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J. Clin. Oncol.26(7),1142–1147 (2008).
      MedlineGoogle Scholar
    • 7  Strong VE, D’Angelica M, Tang L et al.: Laparoscopic adrenalectomy for isolated adrenal metastasis. Ann. Surg. Oncol.14(12),3392–3400 (2007).
      MedlineGoogle Scholar
    • 8  Adler JT, Mack E, Chen H: Equal oncologic results for laparoscopic and open resection of adrenal metastases. J. Surg. Res.140(2),159–164 (2007).
      MedlineGoogle Scholar
    • 9  Kuehl H, Stattaus J, Forsting M, Antoch G: Transhepatic CT-guided radiofrequency ablation of adrenal metastases from hepatocellular carcinoma. Cardiovasc. Intervent. Radiol.31(6),1210–1214 (2008).
      MedlineGoogle Scholar
    • 10  Carrafiello G, Lagana D, Recaldini C et al.: Imaging-guided percutaneous radiofrequency ablation of adrenal metastases: preliminary results at a single institution with a single device. Cardiovasc. Intervent. Radiol.31(4),762–767 (2008).
      Medline CASGoogle Scholar
    • 11  Mayo-Smith WW, Dupuy DE: Adrenal neoplasms: CT-guided radiofrequency ablation-preliminary results. Radiology231(1),225–230 (2004).
      MedlineGoogle Scholar
    • 12  Wood BJ, Abraham J, Hvizda JL, Alexander HR, Fojo T: Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer97(3),554–560 (2003).
      MedlineGoogle Scholar
    • 13  Park JS, Yoon DS, Kim KS et al.: What is the best treatment modality for adrenal metastasis from hepatocellular carcinoma? J. Surg. Oncol.96(1),32–36 (2007).
      MedlineGoogle Scholar
    • 14  Hsieh MH, Lin ZY, Huang CJ, Shih MC, Chuang WL: Management of bilateral adrenal metastases from hepatocellular carcinoma: a case report. Kaohsiung J. Med. Sci.21(8),371–376 (2005).
      MedlineGoogle Scholar
    • 15  Soffen EM, Solin LJ, Rubenstein JH, Hanks GE: Palliative radiotherapy for symptomatic adrenal metastases. Cancer65(6),1318–1320 (1990).
      Medline CASGoogle Scholar
    • 16  Short S, Chaturvedi A, Leslie MD: Palliation of symptomatic adrenal gland metastases by radiotherapy. Clin. Oncol. (R. Coll. Radiol.)8(6),387–389 (1996).
      Medline CASGoogle Scholar
    • 17  Soejima T, Hirota S, Hishikawa Y et al.: [Radiation therapy for adrenal metastases.] Nippon Igaku Hoshasen Gakkai Zasshi57(12),801–804 (1997).
      Medline CASGoogle Scholar
    • 18  Miyaji N, Miki T, Itoh Y et al.: Radiotherapy for adrenal gland metastasis from lung cancer: report of three cases. Radiat. Med.17(1),71–75 (1999).
      Medline CASGoogle Scholar
    • 19  Zeng ZC, Tang ZY, Fan J et al.: Radiation therapy for adrenal gland metastases from hepatocellular carcinoma. Jpn. J. Clin. Oncol.35(2),61–67 (2005).
      MedlineGoogle Scholar
    • 20  Katoh N, Onimaru R, Sakuhara Y et al.: Real-time tumor-tracking radiotherapy for adrenal tumors. Radiother. Oncol.87(3),418–424 (2008).
      MedlineGoogle Scholar
    • 21  Jang JW, Kay CS, You CR et al.: Simultaneous multitarget irradiation using helical tomotherapy for advanced hepatocellular carcinoma with multiple extrahepatic metastases. Int. J. Radiat. Oncol. Biol. Phys.74(2),412–418 (2009).
      MedlineGoogle Scholar
    • 22  Chawla S, Chen Y, Katz AW et al.: Stereotactic body radiotherapy for treatment of adrenal metastases. Int. J. Rad. Onc. Biol. Phys.75(1),71–75 (2009).▪▪ Largest single institution series studying the use of stereotactic body radiation therapy for the treatment of adrenal metastases to which the present study makes comparisons.
      MedlineGoogle Scholar
    • 23  Luketich JD, Burt ME: Does resection of adrenal metastases from non-small-cell lung cancer improve survival? Ann. Thorac. Surg.62(6),1614–1616 (1996).▪ Rationale of treating metastases localized to the adrenal gland.
      Medline CASGoogle Scholar
    • 24  Paul CA, Virgo KS, Wade TP, Audisio RA, Johnson FE: Adrenalectomy for isolated adrenal metastases from non-adrenal cancer. Int. J. Oncol.17(1),181–187 (2000).
      Medline CASGoogle Scholar
    • 25  Timmerman R, Paulus R, Galvin J et al.: Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA303(11),1070–1076 (2010).
      Medline CASGoogle Scholar
    • 26  Fakiris AJ, McGarry RC, Yiannoutsos CT et al.: Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective Phase II study. Int. J. Radiat. Oncol. Biol. Phys.75,677–682 (2009).
      MedlineGoogle Scholar
    • 27  Baumann P, Nyman J, Hoyer M et al.: Outcome in a prospective Phase II trial of medically inoperable stage I non-small-cell lung cancer patients with stereotactic body radiotherapy. J. Clin. Oncol.27(20),3290–3296 (2009).
      MedlineGoogle Scholar
    • 28  Onishi H, Shirato H, Nagata Y et al.: Hypofractionated stereotactic radiotherapy (HypoFXSRT) for state 1 non-small-cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J. Thorac. Oncol.2,S94–S100 (2007).
      MedlineGoogle Scholar